Roy Doumani is Director at Kite Pharma, Inc. (KITE). They have made 3 open-market trades across 1 company since 2016, most recently 2017-10-03.
CIK 0001230232
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KITE | 1,807 | $325K |
Shares reported on the most recent Form 4, priced at the 2017-10-05 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.